Biopharmaceutical manufacturers are increasingly adopting continuous manufacturing techniques over traditional fed-batch methods for monoclonal antibody (mAb) production. Studies demonstrate continuous bioprocessing using systems like Repligen’s XCell ATF can boost volumetric productivity up to tenfold while reducing facility footprints by 70%. Enzene Biosciences' adoption of fully connected continuous manufacturing (FCCM) resulted in cost of goods reductions of up to 80%, improved scalability, and increased process flexibility. Additionally, continuous approaches reduce environmental impact through lower plastic waste and carbon emissions, and real-time monitoring enables earlier fault detection compared to batch processing.